Travere Therapeutics Price Target Cut to 22.00

TVTX Stock  USD 19.68  0.69  3.39%   
Slightly above 69% of Travere Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Travere Therapeutics suggests that many traders are alarmed. Travere Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Travere Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Travere Therapeutics had its target price dropped by Canaccord Genuity Group from 23.00 to 22.00 in a report released on Monday, Benzinga reports. The firm currently has a buy rating on the stock. Canaccord Genuity Groups price objective indicates a potential upside of 57.26 percent from the companys current price. TVTX

Read at thelincolnianonline.com
news
  

Travere Therapeutics Current Investor Sentiment

Comfort Level 31

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Travere Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Travere Therapeutics.

Travere Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Travere Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Travere Therapeutics Historical Investor Sentiment

Investor biases related to Travere Therapeutics' public news can be used to forecast risks associated with an investment in Travere. The trend in average sentiment can be used to explain how an investor holding Travere can time the market purely based on public headlines and social activities around Travere Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Travere Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Travere Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Travere Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Travere Therapeutics.

Travere Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts

Travere Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Travere Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Travere Therapeutics' options.

Travere Therapeutics Fundamental Analysis

We analyze Travere Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Travere Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Travere Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Travere Therapeutics stock to make a market-neutral strategy. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with similar companies.

Peers

Travere Therapeutics Related Equities

ANABAnaptysBio   1.61   
0%
50.0%
CYTKCytokinetics   0.47   
0%
14.0%
APLSApellis Pharmaceuticals   0.04   
1.0%
0%
NUVLNuvalent   0.77   
23.0%
0%
MGTXMeiraGTx Holdings   0.81   
25.0%
0%
GPCRStructure Therapeutics   0.85   
26.0%
0%
LEGNLegend Biotech   0.93   
28.0%
0%
PTGXProtagonist Therapeutics   1.13   
35.0%
0%
VTYXVentyx Biosciences   1.63   
50.0%
0%
KROSKeros Therapeutics   1.82   
56.0%
0%
PCVXVaxcyte   1.85   
57.0%
0%
RVMDRevolution Medicines   1.97   
61.0%
0%
AKROAkero Therapeutics   1.97   
61.0%
0%
COGTCogent Biosciences   1.97   
61.0%
0%
IDYAIdeaya Biosciences   2.18   
67.0%
0%
RNAAvidity Biosciences   2.95   
91.0%
0%
STOKStoke Therapeutics   3.22   
100.0%
0%

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.